Research programme: antibacterials - iNtRON Biotechnology

Drug Profile

Research programme: antibacterials - iNtRON Biotechnology

Alternative Names: Bacteriophage-based antibacterials - iNtRON Biotechnology; Bio-drug therapeutics for superbacteria - iNtRON Biotechnology; N-Rephasin® NPA200; NPA 200

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iNtRON biotechnology
  • Developer iNtRON Biotechnology
  • Class Bacteriophages; Proteins
  • Mechanism of Action Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in South Korea (Parenteral, Injection)
  • 21 Jul 2015 LLC Darleks in-licenses N-Rephasin® bacteriophage technology from iNtRON Biotechnology
  • 14 Mar 2013 Preclinical trials in Bacterial infections in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top